As required by 45 CFR part 75 Appendix XII of the Uniform Guidance, non-federal entities (NFEs) are required to disclose in FAPIIS any information about criminal, civil, and administrative proceedings, and/or affirm that there is no new information to provide. This applies to NFEs that receive Federal awards (currently active grants, cooperative agreements, and procurement contracts) greater than \$10,000,000 for any period of time during the period of performance of an award/project.

Mandatory Disclosure Requirements

As required by 2 CFR part 200 of the Uniform Guidance, and the HHS implementing regulations at 45 CFR part 75, effective January 1, 2016, the IHS must require a non-federal entity or an applicant for a Federal award to disclose, in a timely manner, in writing to the IHS or pass-through entity all violations of Federal criminal law involving fraud, bribery,or gratutity violations potentially affecting the Federal award.

Submission is required for all applicants and recipients, in writing, to the IHS and to the HHS Office of Inspector General all information related to violations of Federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the Federal award. 45 CFR 75.113.

Disclosures must be sent in writing to: U.S. Department of Health and Human Services, Indian Health Service, Division of Grants Management, ATTN: Robert Tarwater, Director, 5600 Fishers Lane, Mailstop 09E70, Rockville, Maryland 20857.

(Include "Mandatory Grant Disclosures" in subject line)

*Office:* (301) 443–5204.

Fax: (301) 594–0899.

Email: Robert.Tarwater@ihs.gov. AND

U.S. Department of Health and Human Services, Office of Inspector General, ATTN: Mandatory Grant Disclosures, Intake Coordinator, 330 Independence Avenue SW., Cohen Building, Room 5527, Washington, DC 20201.

URL: http://oig.hhs.gov/fraud/ reportfraud/index.asp.

(Include "Mandatory Grant Disclosures" in subject line).

*Fax:* (202) 205–0604 (Include

"Mandatory Grant Disclosures" in subject line) or

Email:

MandatoryGranteeDisclosures@ oig.hhs.gov.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371 Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 & 376 and 31 U.S.C. 3321).

# VII. Agency Contacts

1. Questions on the programmatic issues may be directed to: Roselyn Tso, Acting Director, Office of Direct Service and Contracting Tribes, Indian Health Service, 5600 Fishers Lane, Mail Stop 08E17, Rockville, MD 20857, Telephone: (301) 443–1104, Email: roselyn.tso@ihs.gov.

2. Questions on grants management and fiscal matters may be directed to:

Ms. Vanietta Armstrong, Grants Management Specialist, Indian Health Service, OMS/DGM, 5600 Fishers Lane, Mail Stop 09E70, Rockville, MD 20857, Telephone: (301) 443–4792, Fax: (301) 594–0899, Email: *vanietta.armstrong@ ihs.gov.* 

3. Questions on systems matters may be directed to: Mr. Paul Gettys, Grant Systems Coordinator, 5600 Fishers Lane, Mail Stop 09E70, Rockville, MD 20857, Phone: (301) 443–2114; or the DGM main line (301) 443–5204, Fax: (301) 594–0899, E-Mail: *Paul.Gettys*@ *ihs.gov*.

#### VIII. Other Information

The Public Health Service strongly encourages all cooperative agreement and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of the facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the HHS mission to protect and advance the physical and mental health of the American people.

Dated: April 24, 2017.

RADM Chris Buchanan, R.E.H.S., M.P.H.

Assistant Surgeon General, USPHS Acting Director

Indian Health Service

### **VIII. Other Information**

The PHS strongly encourages all cooperative agreement and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103–227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of the facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the HHS mission to protect and advance the physical and mental health of the American people.

Dated: April 24, 2017.

#### Elizabeth A. Fowler,

Deputy Director for Management Operations, Indian Health Service.

[FR Doc. 2017–08775 Filed 4–28–17; 8:45 am] BILLING CODE 4165–16–P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

### National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel; IMAT R21 Review.

Date: May 17, 2017.

Time: 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W114, Rockville, MD 20850 (Telephone Conference Call).

Contact Person: Jeffrey E. DeClue, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W114, Bethesda, MD 20892– 9750, 240–276–6371, decluej@mail.nih.gov.

*Name of Committee:* National Cancer Institute Special Emphasis Panel; IMAT R33 Review.

*Date:* May 18, 2017.

*Time:* 11:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W114, Rockville, MD 20850 (Telephone Conference Call).

*Contact Person:* Jeffrey E. DeClue, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W114, Bethesda, MD 20892– 9750, 240–276–6371, *decluej@mail.nih.gov.*  Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Clinical and Translational R21 & Omnibus R03: SEP–2.

*Date:* June 5, 2017.

*Time:* 8:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Westin Arlington Gateway Hotel, 801 N. Glebe Road, Arlington, VA 22203.

*Contact Person:* Robert S. Coyne, Ph.D., Scientific Review Officer, Special Review Branch Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W236, Bethesda, MD 20892–9750, 240–276–5120, *robert.coyne@ nih.gov.* 

*Name of Committee:* National Cancer Institute Special Emphasis Panel; NCI Program Project I (P01).

*Date:* June 7–8, 2017.

*Time:* 8:00 a.m. to 12:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

Contact Person: Sanita Bharti, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W618, Bethesda, MD 20892–9750, 240–276–5909, sanitab@mail.nih.gov.

*Name of Committee:* National Cancer Institute Special Emphasis Panel; NCI Clinical and Translational R21 & Omnibus R03: SEP 6.

*Date:* June 13–14, 2017.

*Time:* 8:00 a.m. to 12:00 p.m. *Agenda:* To review and evaluate grant

applications. *Place:* Gaithersburg Marriott

Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878.

Contact Person: Hasan Siddiqui, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W240, Bethesda, MD 20892–9750, 240–276–5122, hasan.siddiqui@ nih.gov.

Name of Committee: National Cancer Institute, Initial Review Group; Subcommittee F—Institutional Training and

Education.

*Date:* June 13, 2017.

*Time:* 12:00 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W606, Bethesda, MD 20892–9750 (Telephone Conference Call).

*Contact Person:* Timothy C. Meeker, MD, Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W606, Bethesda, MD 20892–9750, 240–276–6464, *meekert@mail.nih.gov.* 

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Youth Enjoy Science (YES).

Date: June 21, 2017.

*Time:* 1:00 p.m. to 4:00 p.m. *Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W530, Rockville, MD 20850 (Telephone Conference Call).

*Contact Person:* Shamala K. Srinivas, Ph.D., Scientific Review Officer, Office of Referral, Review, and Program Coordination, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W530, Bethesda, MD 20892– 9750, 240–276–6430, *shamala@mail.nih.gov*.

Name of Committee: National Cancer Institute Special Emphasis Panel; Canine Immunotherapy Trials RFA CA–17–001 (U01) & RFA CA–17–002 (U24).

Date: June 22, 2017.

*Time:* 9:00 a.m. to 5:00 p.m. *Agenda:* To review and evaluate grant applications.

<sup>^</sup>*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 1E030, Bethesda, MD 20892–9750 (Telephone Conference Call).

*Contact Person:* Caterina Bianco, MD, Ph.D., Acting Chief, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W110, Bethesda, MD 20892–9750, 240–276–6459, *biancoc@mail.nih.gov.* 

*Name of Committee:* National Cancer Institute Special Emphasis Panel; NCI R01 Meeting Teleconference.

Date: June 22, 2017.

*Time:* 11:00 a.m. to 3:00 p.m. *Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W618, Bethesda, MD 20892–9750 (Telephone Conference Call).

*Contact Person:* Sanita Bharti, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W618, Bethesda, MD 20892–9750, 240–276–5909, *sanitab@mail.nih.gov.* 

Name of Committee: National Cancer Institute Special Emphasis Panel; PDAC U01 Review.

*Date:* June 26, 2017.

Time: 11:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W126, Bethesda, MD 20892–9750 (Telephone Conference Call).

Contact Person: Caron A. Lyman, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W126, Bethesda, MD 20892–9750, 240–276–6348, *lymanc@mail.nih.gov.* 

*Name of Committee:* National Cancer Institute Special Emphasis Panel; NCI R03 & Clinical and Translational R21: SEP–7.

*Date:* June 28–29, 2017.

*Time:* 8:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

*Place:* Bethesda North Marriott Hotel and Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852.

Contact Person: Beyeong-Chul Lee, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W238, Bethesda, MD 20892–9750, 240–276–7755, byeong-chel.lee@nih.gov.

*Name of Committee:* National Cancer Institute Special Emphasis Panel; CIMAC and CIDC U24 Review.

Date: July 13, 2017.

*Time:* 11:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W030, Bethesda, MD 20892–9750, (Telephone Conference Call).

Contact Person: Majed Hamawy, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W120, Bethesda, MD 20892–9750, 240–276–6457, mh101v@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: April 25, 2017.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–08704 Filed 4–28–17; 8:45 am]

BILLING CODE 4140-01-P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

## National Institutes of Health

## Submission for OMB Review; 30-Day Comment Request; Generic Clearance for Surveys of Customers and Partners of the Office of Extramural Research of the National Institutes of Health

**AGENCY:** National Institutes of Health, Department of Health and Human Services.

# **ACTION:** Notice.

**SUMMARY:** In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the **Federal Register** on February 16, 2017, and allowed 60-days for public comment. No public